- Home
- / Daewoong Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Daewoong Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩150.4 K
2024-10-29
Market Capitalization
₩1.7 T
2024-10-29
Revenue
₩2.1 T
FY, 2025
CreditSafe Score
?
Score changed on Jul 18, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2T | 1.4T | 1.4T | 1.5T | 1.7T | 1.8T | 1.9T | 2.1T |
| Cost of goods sold | 540.6B | 599.4B | 594.3B | 605.6B | 636.1B | 836.4B | 30.0B | (2.0B) |
| Gross profit | 695.0B | 770.0B | 771.6B | 912.1B | 1.1T | 981.0B | 1.9T | 2.1T |
| Gross profit margin, % | 56.4% | 56.9% | 60.4% | 62.8% | 54.1% | 98.7% | 100.5% | |
| Operating expense total | 546.0B | 611.2B | 616.3B | 674.7B | 805.9B | 727.6B | 755.0B | 1.7T |
| Depreciation and amortization | 74.0B | 56.9B | 54.7B | 49.4B | 53.3B | 56.6B | 74.3B | 77.5B |
| EBITDA | 148.7B | 155.0B | 154.0B | 237.4B | 260.4B | 278.3B | 246.9B | 366.5B |
| EBITDA margin, % | 11.4% | 11.4% | 15.7% | 15.3% | 15.3% | 12.7% | 17.7% | |
| EBIT | 71.2B | 84.0B | 87.7B | 102.3B | 153.2B | 205.1B | 137.3B | 266.3B |
| EBIT margin, % | 6.2% | 6.5% | 6.8% | 9.0% | 11.3% | 7.1% | 12.9% | |
| Interest income | 4.3B | 4.9B | 4.8B | 4.3B | 11.4B | 9.3B | 9.2B | 6.2B |
| Interest expense | 9.6B | 10.1B | 10.5B | 10.3B | 8.4B | 14.0B | 7.6B | 13.9B |
| Pre tax profit | 60.8B | 81.3B | 144.6B | 113.4B | 154.9B | 202.5B | 115.8B | 243.6B |
| Income tax expense | 28.0B | 9.9B | 26.2B | 13.4B | 34.7B | 11.1B | 46.9B | 15.7B |
| Net Income | 32.7B | 71.3B | 118.4B | 100.0B | 120.3B | 191.4B | 68.9B | 227.9B |